瑞马唑仑与丙泊酚用于药物诱导睡眠内镜的比较:一项随机临床试验
该前瞻性单中心随机临床试验在阻塞性睡眠呼吸暂停低通气综合征(OSAHS)患者中比较瑞马唑仑与丙泊酚用于药物诱导睡眠内镜(DISE)的效果。瑞马唑仑组低氧血症发生率显著低于丙泊酚组(25.00% vs 62.50%,相对危险度0.40,95%CI 0.20-0.74,p<.01)。瑞马唑仑在DISE中镇静效果满意,低氧血症发生率更低,安全性更高。
要点
- 瑞马唑仑组低氧血症发生率25.00%,显著低于丙泊酚组的62.50%(p<.01)。
- 两组镇静成功率无显著差异(96.88% vs 81.25%,p=.10)。
- 瑞马唑仑组至少发生1次关注事件的比例低于丙泊酚组(43.75% vs 96.88%,p<.01)。
核心结论
- 瑞马唑仑在DISE中可提供满意的镇静效果,低氧血症发生率更低,安全性高于丙泊酚。
研究设计与样本
- 前瞻性、单中心、随机临床试验,纳入64例接受DISE的OSAHS患者,随机分为瑞马唑仑组或丙泊酚组。
- 研究地点为中南大学湘雅医院。
主要发现
- 瑞马唑仑组低氧血症发生率25.00% vs 丙泊酚组62.50%,相对危险度0.40(95%CI 0.20-0.74,p<.01)。
- 瑞马唑仑组与丙泊酚组镇静成功率分别为96.88% vs 81.25%,相对危险度1.19(95%CI 1.01-1.50,p=.10),无显著差异。
- 瑞马唑仑组至少发生1次关注事件的比例43.75% vs 丙泊酚组96.88%,相对危险度0.45(95%CI 0.29-0.63,p<.01)。
- 次要结局包括严重低氧血症(SpO2<80%)发生率、SpO2最低值及关注事件(注射痛、心动过缓、呼吸频率下降)发生率。
关键数值与推荐
- 主要结局为DISE期间低氧血症(脉搏血氧饱和度SpO2<90%)发生率。
- 次要结局包括严重低氧血症(SpO2<80%)发生率、SpO2最低值、镇静成功率(按用药方案完成DISE)及关注事件发生率。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of remimazolam with those of propofol for drug-induced sleep endoscopy (DISE) in patients with obstructive sleep apnea-hypopnea syndrome (OSAHS). STUDY DESIGN: A prospective, single-center, randomized clinical trial. SETTING: Xiangya Hospital of Central South University. METHODS: Patients with OSAHS receiving DISE were randomly assigned to either the remimazolam or propofol group. The primary outcome was the incidence of hypoxemia (pulse oxygen saturation [SpO2 ] < 90%) during DISE. The secondary outcomes were the incidence of severe hypoxemia (SpO2 < 80%), the minimal value of SpO2 , sedation success rate (completion of DISE according to the medication regimen), and incidence of events of interest (including injection pain, bradycardia, and decreased respiratory rate). RESULTS: Sixty-four patients were included in this study. The incidence of hypoxemia was significantly lower in the remimazolam than in the propofol group (25.00% vs 62.50%, respectively; relative risk, 0.40; 95% confidence interval [CI], 0.20-0.74; p < .01). There was no significant difference in the sedation success rate between the remimazolam and propofol groups (96.88% vs 81.25%, respectively; relative risk, 1.19; 95% CI, 1.01-1.50; p = .10). The incidence of at least 1 event of interest was lower in the remimazolam than in the propofol group (43.75% vs 96.88%, respectively; relative risk, 0.45; 95% CI, 0.29-0.63; p < .01). CONCLUSION: Remimazolam can present satisfactory sedative efficacy in DISE, with a lower incidence of hypoxemia and a higher safety profile than propofol.
引用
- Zhang J, Zhang Y, Fang X, et al. Comparison of Remimazolam and Propofol for Drug-Induced Sleep Endoscopy: A Randomized Clinical Trial. Otolaryngol Head Neck Surg. 2023. PMID: 37264980. doi:10.1002/ohn.387
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。